Imbalance of plasma amino acids, metabolites and lipids in patients with lysinuric protein intolerance (LPI)

被引:11
|
作者
Kurko, Johanna [1 ]
Tringham, Maaria [1 ]
Tanner, Laura [1 ,2 ]
Nanto-Salonen, Kirsti [3 ,4 ]
Vaha-Makila, Mari [3 ,4 ]
Nygren, Heli [5 ]
Poho, Paivi [6 ]
Lietzen, Niina [7 ,8 ]
Mattila, Ismo [9 ]
Olkku, Anu [10 ]
Hyotylainen, Tuulia [9 ]
Oresic, Matej [9 ]
Simell, Olli [3 ,4 ]
Niinikoski, Harri [3 ,4 ]
Mykkanen, Juha [3 ,4 ,11 ]
机构
[1] Univ Turku, Dept Med Biochem & Genet, Kiinamyllynkatu 10, Turku 20520, Finland
[2] Turku Univ Hosp, Dept Clin Genet, Kiinamyllynkatu 4-8, Turku 20521, Finland
[3] Turku Univ Hosp, Dept Pediat, Kiinamyllynkatu 4-8,PL 52, Turku 20521, Finland
[4] Univ Turku, Kiinamyllynkatu 4-8,PL 52, Turku 20521, Finland
[5] VTT Tech Res Ctr Finland, Tietotie 2,POB 1000, Espoo 02044, Finland
[6] Univ Helsinki, Fac Pharm, Viikinkaari 5 E,POB 56, Helsinki 00014, Finland
[7] Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6, Turku 20520, Finland
[8] Abo Akad Univ, Tykistokatu 6, Turku 20520, Finland
[9] Steno Diabet Ctr AS, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark
[10] Eastern Finland Lab Ctr, Puijonlaaksontie 2, Kuopio 70210, Finland
[11] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Kiinamyllynkatu 10, Turku 20520, Finland
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2016年 / 65卷 / 09期
关键词
Lysinuric protein intolerance; Chronic kidney disease; Combined hyperlipidemia; Metabolomics; Lipidomics; CHRONIC KIDNEY-DISEASE; BETA-AMINOISOBUTYRIC ACID; HEPATIC STEATOSIS; OXIDATIVE STRESS; RENAL-FAILURE; INFLAMMATION; TRANSPORT; SUPPLEMENTATION; IDENTIFICATION; MALNUTRITION;
D O I
10.1016/j.metabol.2016.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Lysinuric protein intolerance (LPI [MIM 2227001) is an aminoaciduria with defective transport of cationic amino acids in epithelial cells in the small intestine and proximal kidney tubules due to mutations in the SLC7A7 gene. LPI is characterized by protein malnutrition, failure to thrive and hyperammonemia. Many patients also suffer from combined hyperlipidemia and chronic kidney disease (CKD) with an unknown etiology. Methods. Here, we studied the plasma metabolomes of the Finnish LPI patients (n = 26) and healthy control individuals (n = 19) using a targeted platform for analysis of amino acids as well as two analytical platforms with comprehensive coverage of molecular lipids and polar metabolites. Results. Our results demonstrated that LPI patients have a dichotomy of amino acid profiles, with both decreased essential and increased non-essential amino acids. Altered levels of metabolites participating in pathways such as sugar, energy, amino acid and lipid metabolism were observed. Furthermore, of these metabolites, myo-inositol, threonic acid, 2,5-furandicarboxylic acid, galactaric acid, 4-hydroxyphenylacetic acid, indole-3-acetic acid and beta-aminoisobutyric acid associated significantly (P < 0.001) with the CKD status. Lipid analysis showed reduced levels of phosphatidylcholines and elevated levels of triacylglycerols, of which long-chain triacylglycerols associated (P < 0.01) with CKD. Conclusions. This study revealed an amino acid imbalance affecting the basic cellular metabolism, disturbances in plasma lipid composition suggesting hepatic steatosis and fibrosis and novel metabolites correlating with CKD in LPI. In addition, the CKD-associated metabolite profile along with increased nitrite plasma levels suggests that LPI may be characterized by increased oxidative stress and apoptosis, altered microbial metabolism in the intestine and uremic toxicity. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1361 / 1375
页数:15
相关论文
共 50 条
  • [1] CUGC for lysinuric protein intolerance (LPI)
    Diego Martinelli
    Manuel Schiff
    Michela Semeraro
    Emanuele Agolini
    Antonio Novelli
    Carlo Dionisi-Vici
    [J]. European Journal of Human Genetics, 2020, 28 : 1129 - 1134
  • [2] CUGC for lysinuric protein intolerance (LPI)
    Martinelli, Diego
    Schiff, Manuel
    Semeraro, Michela
    Agolini, Emanuele
    Novelli, Antonio
    Dionisi-Vici, Carlo
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (08) : 1129 - 1134
  • [3] Alterations of arginine in Lysinuric Protein Intolerance (LPI) macrophages
    Barilli, Amelia
    Rotoli, Bianca Maria
    Visigalli, Rossana
    Dall'Asta, Valeria
    [J]. FASEB JOURNAL, 2013, 27
  • [4] FIRST POLISH CASES WITH LYSINURIC PROTEIN INTOLERANCE (LPI)
    Rokicki, D.
    Pronicka, E.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 254 - 254
  • [5] TRANSPORT OF HOMOARGININE INTO LIVER SLICES OF PATIENTS WITH LYSINURIC PROTEIN INTOLERANCE (LPI)
    SIMELL, O
    PERHEENTUPA, J
    [J]. PEDIATRIC RESEARCH, 1974, 8 (11) : 904 - 904
  • [6] LYSINURIC PROTEIN INTOLERANCE (LPI) - TREATMENT WITH CITRULLINE AND LYSINE
    RAJANTIE, J
    SIMELL, O
    PERHEENTUPA, J
    [J]. PEDIATRIC RESEARCH, 1979, 13 (01) : 78 - 78
  • [7] LYSINURIC PROTEIN INTOLERANCE (LPI): EXPERIENCE OF A GREEK CENTER
    Augoustides-Savvopoulou, P.
    Ioannou, C.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S85 - S85
  • [8] Macrophages from patients affected by Lysinuric Protein Intolerance (LPI) exhibit an impaired phagocytosis
    Rotoli, Bianca Maria
    Barilli, Amelia
    Visigalli, Rossana
    Dall'Asta, Valeria
    [J]. FASEB JOURNAL, 2012, 26
  • [9] LYSINURIC PROTEIN INTOLERANCE (LPI) - THE DEFECT IN CATIONIC AMINO-ACID-TRANSPORT IS EXPRESSED IN PLASMA-MEMBRANE OF CULTURED FIBROBLASTS
    SIMELL, O
    SMITH, DW
    TENENHOUSE, HS
    SCRIVER, CR
    [J]. PEDIATRIC RESEARCH, 1987, 22 (01) : 97 - 97
  • [10] OROTIC ACIDURIA, AN INDICATOR OF ADEQUACY OF TREATMENT IN LYSINURIC PROTEIN INTOLERANCE (LPI)
    RAJANTIE, J
    SIMELL, O
    PERHEENTUPA, J
    [J]. PEDIATRIC RESEARCH, 1980, 14 (02) : 177 - 177